Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was up 28.6% during trading on Tuesday . The stock traded as high as $5.39 and last traded at $4.72, with a volume of 556,505 shares traded. The stock had previously closed at $3.67.

Several equities research analysts have commented on GLMD shares. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Monday, July 18th. Roth Capital restated a “buy” rating and issued a $6.00 price objective on shares of Galmed Pharmaceuticals in a research report on Wednesday, July 6th. HC Wainwright restated a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, June 30th. Maxim Group restated a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Wednesday, June 8th. Finally, FBR & Co set a $20.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $12.35.

The firm’s market cap is $51.40 million. The stock’s 50-day moving average price is $3.94 and its 200 day moving average price is $4.68.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/galmed-pharmaceuticals-ltd-glmd-shares-up-28-6.html

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. Equities research analysts expect that Galmed Pharmaceuticals Ltd. will post ($1.51) earnings per share for the current fiscal year.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

5 Day Chart for NASDAQ:GLMD

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.